BiotechTube
Regencell Bioscience

Regencell Bioscience

RGCPre-clinical
Hong Kong, Hong Kongregencell.com

Regencell Bioscience combines traditional Chinese medicine with modern biotechnology to develop innovative treatments for autism spectrum disorder, attention deficit hyperactivity disorder (ADHD), and other neurodegenerative conditions. The company operates through its proprietary TCM-based formulations and stem cell therapy platforms, targeting underserved patient populations with limited treatment options. Based in Hong Kong, Regencell aims to bridge Eastern traditional medicine with Western regulatory standards to bring novel therapeutics to global markets.

Market Cap
$12.5B
+2154.5% period
Pipeline
—
Patents
—
Publications
20
indexed

RGC · Stock Price

USD 25.22+24.10 (+2154.52%)

Historical price data

AI Company Overview

Regencell Bioscience combines traditional Chinese medicine with modern biotechnology to develop innovative treatments for autism spectrum disorder, attention deficit hyperactivity disorder (ADHD), and other neurodegenerative conditions. The company operates through its proprietary TCM-based formulations and stem cell therapy platforms, targeting underserved patient populations with limited treatment options. Based in Hong Kong, Regencell aims to bridge Eastern traditional medicine with Western regulatory standards to bring novel therapeutics to global markets.

Neurodevelopmental DisordersNeurodegenerative DiseasesAutism Spectrum DisorderADHD

Technology Platform

Develops novel treatments based on traditional Chinese medicine (TCM) formulations combined with modern biotechnology and stem cell therapies, focusing on neurodegenerative and neurodevelopmental conditions.

Funding History

1
Total raised:$6M
IPO$6MJul 23, 2021

Opportunities

Significant growth potential in bridging traditional Chinese medicine with modern drug development, particularly in underserved neurodevelopmental disorders market.
Access to both Asian markets with TCM acceptance and Western markets seeking alternative treatments.

Risk Factors

Key challenges include proving efficacy of traditional formulations through rigorous clinical trials, navigating complex regulatory pathways for TCM-based therapies, and competing against established pharmaceutical companies with greater resources.

Competitive Landscape

Competes with traditional pharmaceutical companies developing neurological treatments and other companies modernizing traditional medicine approaches. Differentiated by its TCM focus and strategic Hong Kong positioning for East-West market bridge.